Tariff impacts will vary by individual companies

Rajeev Agrawal, a fund manager at DoorDarshi India Fund, believes that the impact of tariffs under former President Trump will affect specific companies rather than entire sectors. He notes that various companies have different levels of exports, particularly in sectors like pharmaceuticals, which may face challenges due to US tariffs. Agrawal explains that companies with higher export percentages to the US will feel a stronger impact. He highlights the pharmaceutical industry, especially generic drug manufacturers, as being particularly vulnerable. He emphasizes that the full effects of these tariffs are still uncertain. While Agrawal maintains that his fund's sector allocations remain mostly unchanged, he indicates they have shifted investments from certain companies to others within the same sector. This approach reflects a more targeted strategy based on individual company performance, rather than broad market moves. Looking ahead, Agrawal believes that Trump's approach will continue to involve negotiation tactics. He mentions that the upcoming date of April 2nd is being anticipated in the market, as it may signal changes in tariff strategies. Currently, Agrawal is optimistic about investing in domestic companies, particularly within the lending sector, which he sees as offering potential growth opportunities. He has recently sold off companies that were fully valued to invest in others he finds more promising.